Our pipeline consists of small molecule agents that target cancer signaling pathways, where each program builds on our expertise in precision medicines.
Program
Development Approach
Research
Phase 1 Dose Escalation
Phase 1 Dose Expansion
Registrational
U.S. FDA Approved
Clinical Trial
Menin Inhibitor
KOMZIFTI™
(ziftomenib)*
Monotherapy
Menin Inhibitor
Ziftomenib**
Combination with 7+3(IC)
Combination with venetoclax/azacitidine
Combination with 7+3 and quizartinib
Combination with 7+3 or venetoclax/azacitidine
Combination with gilteritinib
Combinations with FLAG-IDA and LDAC
Monotherapy
Monotherapy
Ziftomenib
Ziftomenib is being investigated in up to 50% of AMLs across NPM1-m, KMT2A-r and FLT3-m AML, and in combination with other cancer therapies.
Farnesyl Transferase Inhibitor
Darlifarnib (KO-2806)
NEXT-GEN FTI
Combination with cabozantinib
Combination with adagrasib
Darlifarnib (KO-2806)
Darlifarnib (KO-2806) is an investigational next-generation farnesyl transferase inhibitor (FTI). Combination therapy using FTIs has the potential to address drug resistance and provide deeper and more durable anti-tumor activity. Darlifarnib is not FDA-approved and safety and efficacy have not been established.
Farnesyl Transferase Inhibitors
Tipifarnib
Combination with alpelisib
Tipifarnib
Tipifarnib is an oral investigational FTI that is not FDA-approved. Safety and efficacy have not been established.
Next-Gen Menin Inhibitor (KO-7246)
The investigational agents and investigational uses of marketed products identified above have not been approved by the US Food and Drug Administration. Safety and efficacy have not been established.
-m, mutated; -r, rearranged; R/R, relapsed/refractory; 7+3, 7 days of cytarabine + 3 days of daunorubicin; IC, intensive chemotherapy; NIC, non-intensive chemotherapy; ALL, acute lymphoblastic leukemia; FLAG-IDA: fludarabine, high-dose cytarabine (Ara-C), granulocyte-colony stimulating factor (G-CSF) and idarubicin; LDAC: Low-dose cytarabine
Progress bars indicate the stage of development based on ongoing or completed activities. A partial bar indicates a phase in progress; a full bar indicates completion of a phase. Bars do not represent scale, duration, or likelihood of success.
*KOMZIFTI (ziftomenib) was approved by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options.
**In Nov. 2024, Kura, Kyowa Kirin Co., Ltd. and Kyowa Kirin, Inc. entered into a global strategic collaboration agreement to develop and commercialize ziftomenib for AML and other hematologic malignancies.